![]() |
市場調査レポート
商品コード
704952
消化器治療薬の世界市場 - 成長率、動向、予測:2019年~2024年Gastrointestinal Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025) |
消化器治療薬の世界市場 - 成長率、動向、予測:2019年~2024年 |
出版日: 2020年08月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 113 Pages
納期: 2-3営業日
|
消化器治療薬市場は、主に消化管疾患につながるライフスタイルの変化によって促進されています。2017年のNational Health Interview Surveyによると、米国において1530万人の成人が潰瘍と診断されました。
当レポートでは、世界における消化器治療薬市場の分析を薬剤タイプ・剤形・適応症および地域別に提供しており、競合情勢、主要企業のプロファイルなどとともにお届けします。
The gastrointestinal therapeutics market is expected to register a healthy CAGR of nearly 6.5 % during the forecast period. The major factors that contribute to the growth of the gastrointestinal therapeutics market include the increasing prevalence of gastrointestinal diseases due to unhealthy dietary habits, additional numbers of clinical trials with accurate results, increasing healthcare expenditure, and growth in the geriatric population.
According to the National Health Interview Survey (2017), 15.3 million adults were diagnosed with ulcers in the United States. Therefore a wide range of new generation therapeutics is found targeting that include novel small molecules and cellular therapy are currently under investigation. Other driving factors include the rising surgical treatments and hospitalizations, due to GI diseases, and increasing R&D investments by biopharmaceutical companies in developing biologics and biosimilars.
However, risk factors, such as those related to the physiological, behavioral, psychosocial, and socio-environmental aspects, restrict the populations from reporting the diseases early, which reflects the low awareness and the economic burden. These risk factors and the increasing number of patent expirations restrict the growth of the gastrointestinal therapeutics market.
Ulcerative Colitis is Found to Witness Healthy CAGR Over the Forecast Period
Ulcerative colitis is found to witness rapid growth in the gastrointestinal therapeutics market. The growth of this segment can be attributed to the easy availability of drugs in the market to treat this condition. The segment is also anticipated to grow at a considerable rate owing to high clinical urgency to curb the growing prevalence of ulcerative colitis. This high prevalence is due to poor prognosis and consumption of unhealthy food, which may result in a high probability of disease recurrence. In addition, Takeda Pharmaceuticals, Jassen Pharmaceuticals, and Pfizer are among the major global companies that have established themselves with their products for the treatment of inflammatory ulcerative colitis.
Asia-Pacific is the Fastest Growing Region in the Gastrointestinal Therapeutics Market
In recent years, the Asian countries have been witnessing a similar growth trend to that of the western developed markets, particularly owing to the increasing economic growth, along with the privatization, competitive site experience, technological expertise, infrastructure, and the scale to manage large-scale clinical trials across India, China, Japan, South Korea, and other countries. The unmet medical need and potential market opportunity have accelerated the partnerships between major global companies and Asian pharmaceutical companies, for the development and exploration of commercial potential in the growth of the pharmaceutical business.
The North America market has also been accounted for the largest share and is expected to maintain its position during the forecast period. This substantial share can be attributed to unprecedented change in lifestyle, resulting in greater incidence of gastrointestinal diseases.
The major players in the gastrointestinal therapeutics market include Abbott, Allergan, GlaxoSmithKline PLC, Pfizer, and Takeda Pharmaceutical Company Limited, among others. These key players have extensively employed competition sustainability strategies such as new product development and regional and distribution channel expansion to gain a higher share in the market. Moreover, increased focus on refining operation and supply chain management has facilitated key players to maintain a competitive edge.